Intranasal administration of recombinant human cartilage glycoprotein-39 as a treatment for rheumatoid arthritis: a phase II, multicentre, double-blind, randomised, placebo-controlled, parallel-group, dose-finding trial

R.B.M. Landewe, J.G.A. Houbiers, F. Bosch, J. in't Hout, P.C.P.M. Verschueren, J.H. Meijerink, F.H.J. van den Hoogen, B.A. Masek, G.A.W. Bruyn, J.M.G.W. Wouters, A.E. Voskuyl, JM van Laar, J.J.W. Bijlsma, D.M.F.M. van der Heijde, F.C. Breedveld, L.B.A. van de Putte, A.M.M. Miltenburg, F. de Keyser

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)1655-1659
JournalAnnals of the Rheumatic Diseases
Issue number9
Publication statusPublished - 2010

Cite this